Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor by Hogg, Ron C. et al.
Single Amino Acid Substitutions in a-Conotoxin PnIA Shift
Selectivity for Subtypes of the Mammalian Neuronal Nicotinic
Acetylcholine Receptor*
(Received for publication, July 22, 1999, and in revised form, September 27, 1999)
Ron C. Hogg‡, Les P. Miranda§, David J. Craik§¶, Richard J. Lewis‡§, Paul F. Alewood§,
and David J. Adams‡i
From the ‡Department of Physiology and Pharmacology and §Centre for Drug Design and Development,
University of Queensland, Brisbane, Queensland 4072, Australia
The a-conotoxins, a class of nicotinic acetylcholine
receptor (nAChR) antagonists, are emerging as impor-
tant probes of the role played by different nAChR sub-
types in cell function and communication. In this study,
the native a-conotoxins PnIA and PnIB were found to
cause concentration-dependent inhibition of the ACh-
induced current in all rat parasympathetic neurons ex-
amined, with IC50 values of 14 and 33 nM, and a maximal
reduction in current amplitude of 87% and 71%, respec-
tively. The modified a-conotoxin [N11S]PnIA reduced
the ACh-induced current with an IC50 value of 375 nM
and a maximally effective concentration caused 91%
block. [A10L]PnIA was the most potent inhibitor, reduc-
ing the ACh-induced current in ;80% of neurons, with
an IC50 value of 1.4 nM and 46% maximal block of the
total current. The residual current was not inhibited
further by a-bungarotoxin, but was further reduced by
the a-conotoxins PnIA or PnIB, and by mecamylamine.
1H NMR studies indicate that PnIA, PnIB, and the ana-
logues, [A10L]PnIA and [N11S]PnIA, have identical
backbone structures. We propose that positions 10 and
11 of PnIA and PnIB influence potency and determine
selectivity among a7 and other nAChR subtypes, includ-
ing a3b2 and a3b4. Four distinct components of the nic-
otinic ACh-induced current in mammalian parasym-
pathetic neurons have been dissected with these
conopeptides.
Conotoxins are cysteine-rich peptides from the venom of the
predatory marine snail of the genus Conus. These toxins are
classified according to their primary structure and biological
activity and include the a-conotoxin class, which possess a
two-loop framework containing two disulfide bonds and are
specific inhibitors of nicotinic acetylcholine receptors
(nAChRs).1 Native neuronal nAChRs are composed from a
number of distinct subunits (a2–a7 and a9; b2–b4), which
combine to form functional receptors showing a range of phar-
macological properties. PnIA and PnIB2 are 16-residue pep-
tides isolated from the venom of the molluscivorous Conus
pennaceus that differ by two amino acids at positions 10 and 11
(see Table I). PnIA and PnIB were originally reported to block
ACh-evoked responses in Aplysia neurons (1) and, more re-
cently, to exhibit activity in bovine adrenal chromaffin cells,
but not at the mammalian neuromuscular junction (2).
The x-ray crystal structures of both PnIA (6) and PnIB (7)
are similar, comprising an a-helix between residues 5 and 12, a
310 helical turn at the N terminus, and consecutive b-turns at
the C terminus. In both structures, the side chains of residues
10 and 11 are exposed on the surface of the molecules and
hence mutation of these residues would not be expected to
produce significant changes in the global fold. Data obtained
from 1H NMR experiments in the current study confirm this is
indeed the case. The high degree of surface exposure of these
residues and their lack of structural perturbation means that
changes in activity among these peptides can be correlated
directly to different residue side chains having different bind-
ing interactions at different nAChR subtypes.
Preliminary studies have shown that PnIA and PnIB differ-
entially inhibit the nicotine-induced catecholamine release
from bovine chromaffin cells (2). Differences in potency must be
due to the residues at positions 10 and 11 of these conotoxins.
Position 10 is of particular interest as this position typically
contains different hydrophobic residues in other neuronal
nAChR-selective conotoxins, EpI (3), MII (4), and ImI (5). To
further elucidate the role of the residues at positions 10 and 11
in conferring nAChR subtype selectivity, the modified toxins
[A10L]PnIA and [N11S]PnIA (see Table I) were synthesized.
The aim of this study was to determine the selectivity of both
the native and modified a-conotoxins PnIA and PnIB for the
different nAChR subtypes, which constitute the whole-cell
ACh-induced current in mammalian peripheral neurons, and
to provide information as to the relative contribution of these
nAChR subunits to the whole-cell response. These studies re-
veal significant differences in the selectivity and potency of
PnIA and PnIB that arise through a key mutation at position
10 of these a-conotoxins.
EXPERIMENTAL PROCEDURES
Materials for Conotoxin Synthesis—N-Boc-L-amino acids and re-
agents used during chain assembly were peptide synthesis grade pur-
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chased from Auspep (Melbourne, Australia) and Novabiochem (San
Diego, CA). N-Boc-(L)-amino acid-phenylacetamidomethyl resin and
4-methylbenzylhydrylamine resin were purchased from Applied Biosys-
tems (Foster City, CA) and the Peptide Institute (Osaka, Japan), re-
spectively. Anhydrous dimethyl sulfoxide (Me2SO), p-cresol, p-thiocre-
sol, and resorcinol were purchased from Aldrich (Sydney, Australia).
2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophos-
phate was purchased from Richelieu Biotechnologies (Quebec, Canada)
and O-(7-aza-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaflu-
orophosphate (HATU) was prepared as described previously (8, 9).
Screw-cap glass peptide synthesis reaction vessels (4 ml) with sintered
glass filter frit (10) were obtained from Embell Scientific Glassware
(Queensland, Australia). Anhydrous hydrogen fluoride was purchased
from Matheson Gas (BOC Gases, Melbourne, Australia).
Solid-phase Peptide Synthesis—The chain assemblies of [A10L]PnIA
and [N11S]PnIA were carried using HATU/dimethyl formamide cou-
pling chemistry as described previously (11). The following amino acid
side-chain protection was used: Boc-Asn(xanthyl)-OH, Boc-Asp(O-cyclo-
hexyl)-OH, Boc-Cys(4-methylbenzyl)-OH, Boc-Boc-Ser(O-benzyl)-OH,
and Boc-Tyr(2-bromobenzyloxycarbonyl)-OH. Following chain assem-
blies, the peptide resins were cleaved with hydrogen fluoride/p-cresol/
p-thiocresol (18:1:1, v/v) at 0 °C for 1.5 h. After evaporation of the
hydrogen fluoride, the crude peptide was precipitated and washed with
cold anhydrous diethyl ether (2 3 10 ml), dissolved in 50% aqueous
acetonitrile, and lyophilized after aqueous dilution. The crude lyophi-
lized peptide was reconstituted in 50% acetonitrile and then analyzed
by reversed-phase high pressure liquid chromatography (RP-HPLC)
and electron spray mass spectrometry.
HPLC—Analytical RP-HPLC was performed with a Waters 600E
solvent delivery system. Data were collected by using a 484 absorbance
detector (Applied Biosystems) at 214 nm. Chromatographic separations
were achieved with a 1%/min linear gradient of buffer B in A (A 5 0.1%
trifluoroacetic acid in H2O; B 5 90% CH3CN, 10% H2O, 0.09% triflu-
oroacetic acid) over 80 min at a flow rate of 1 ml/min and 8 ml/min using
Vydac C18 analytical (5 mm, 0.46 3 25 cm) and preparative C18 (10 mm,
2.2 3 25 cm) columns, respectively.
Electron Spray Mass Spectrometry—Mass spectra were acquired on a
PE-Sciex API-III triple quadrupole mass spectrometer equipped with
an Ionspray atmospheric pressure ionization source. Samples (typically
10 ml) were injected into a moving solvent (30 ml/min; 1:1 CH3CN/0.05%
trifluoroacetic acid in H2O) coupled directly to the ionization source by
a fused silica capillary interface (50 mm inner diameter 3 50 cm length).
Sample droplets were ionized at a positive potential of 5 kV and entered
the analyzer through an interface plate and subsequently through an
orifice (100–120 mm in diameter) at a potential of 80–100 V. Full scan
mass spectra were acquired over the mass range of 500–2000 Da with
a scan step size of 0.2 Da. Molecular masses were derived from the
observed m/z values by using MACSPEC 3.3 software (PE-Sciex,
Toronto, Canada). Theoretical monoisotopic and average masses were
calculated by using the MacBiospec program (PE-Sciex).
Folding of [A10L]PnIA and [N11S]PnIA—Air oxidations were car-
ried out by dissolving 10 mg of the lyophilized crude [A10L]PnIA or
[N11S]PnIA crude cleavage material in 45 ml of 1:1 0.1 M NH4HCO3/
isopropyl alcohol (pH 8.25) with vigorous stirring at room temperature
for 1 h. Prior to purification the solution was acidified to pH 3 with
trifluoroacetic acid and analyzed by analytical C4 RP-HPLC using a
linear gradient of 0–80% B at 1%/min while monitoring by UV absorb-
ance at 214 nm and electron spray mass spectrometry. Oxidized
[A10L]PnIA was then purified by semipreparative HPLC using the
same chromatographic conditions in 27% and 32%, yield. The sequences
of the native and modified a-conotoxins used in the present study are
shown in Table I.
Cell Preparation—Parasympathetic neurons from juvenile (2–4
weeks old) rat intracardiac ganglia were isolated and cultured as de-
scribed previously (12). Briefly, rats were killed by decapitation, the
hearts were excised, and the atria were removed and incubated for ;1
h at 37 °C in a saline solution, containing 1 mg/ml collagenase (type 2,
Worthington) and 0.35 mg/ml trypsin (type III). Following enzymatic
treatment, clusters of ganglia were dissected from the epicardial gan-
glion plexus, and neurons were dispersed by trituration in a high
glucose culture medium (Dulbecco’s modified Eagle’s medium, contain-
ing 10% (v/v) fetal calf serum, 100 units/ml penicillin, and 0.1 mg/ml
streptomycin). Dissociated neurons were plated on to laminin-coated
glass coverslips and incubated at 37 °C in a 95% air, 5% CO2 atmo-
sphere for 24–72 h. For experimentation, coverslips containing disso-
ciated neurons were transferred to a perfusion chamber (0.5 ml volume)
mounted on an inverted microscope.
Electrophysiological Recording—Current and voltage recordings
were made using the whole-cell recording configuration of the patch
clamp technique. Electrical access to the cell interior was obtained
using the perforated patch whole-cell recording configuration (13). The
perforated patch configuration allows electrical access to the cell inte-
rior without the loss of cytoplasmic components, which is important in
maintaining functional responses in these cells. A final concentration of
240 mg/ml amphotericin B in 0.4% Me2SO was used in the pipette
solution. Pipettes were pulled from thin walled borosilicate glass (Clark
Electromedical Instruments, Reading, UK) and after fire polishing had
resistances of ;1 MV. Access resistances using the perforated patch
configuration were routinely 4–8 MV before series resistance
compensation.
Membrane currents were recorded using an Axopatch 200A patch
clamp amplifier (Axon Instruments Inc., Foster City, CA), filtered at
2–10 kHz, then digitized at 10–50 kHz (Digidata 1200 interface, Axon
Instruments Inc.) and stored on the hard disc of a PC for viewing and
analysis. Voltage and current protocols were applied using pClamp
software (version 6.1.2, Axon Instruments Inc.). Dose-response curves
were fitted using a Chi square minimization, non-linear curve fitting
routine Microcal Origin 5.0 (Microcal Software Inc., Northampton, MA).
Numerical data are presented as the mean 6 S.E. (n, number of
observations).
Solutions and Reagents—The pipette filling solution for perforated
patch experiments contained (mM): 75 K2SO4, 55 KCl, 5 MgSO4 and 10
HEPES, titrated with N-methyl-D-glucamine to pH 7.2. The control
extracellular solution contained (mM): 140 NaCl, 3 KCl, 2.5 CaCl2, 1.2
MgCl2, 7.7 glucose, and 10 HEPES-NaOH. Acetylcholine (500 mM) and
atropine (100 nM, to inhibit muscarinic ACh receptor activation), were
applied for a duration of 2 s using a rapid piezo application system to
overcome the rapid desensitization of the a7 component (14). Toxins
were applied to the agonist solution as well as the constant perfusing
solution. The time course of solution changes was ,5 ms as determined
from the change in junction potential upon switching from normal bath
solution to one diluted with 2% deionized water. Experiments were
carried out at 22 °C. The osmolality of all solutions was monitored with
a vapor pressure osmometer (Westcor 5500) and was in the range
280–290 mOsmol. All chemicals used were of analytical grade. The
following drugs were used: acetylcholine chloride, atropine hydrochlo-
ride, mecamylamine hydrochloride, cytisine, all supplied by Sigma.
NMR Spectroscopy—For NMR analysis, peptides were dissolved in
30% CD3CN, 70% H2O at a concentration of 1.0 mM as preliminary
spectra of PnIA and PnIB recorded in pure H2O suggested a degree of
conformational averaging3 in aqueous solution. 1H NMR spectra were
recorded at 283 K on a Bruker ARX 500 spectrometer. Total correlation
spectroscopy (TOCSY) spectra (15) were recorded using a MLEV-17
spin lock sequence (16) with a mixing time of 80 ms, and nuclear
Overhauser spectroscopy (NOESY) spectra (17) were recorded with a
200 ms mixing time. The water signal was suppressed in TOCSY and
NOESY spectra using a modified WATERGATE sequence (18) in which
two gradient pulses of 2-ms duration and 6 gauss cm21 strength were
applied either side of a binomial 3–9-19 pulse. Two-dimensional spectra
were acquired over 6024 Hz and collected into 4096 data points with
512 t1 increments of 32–64 scans. Spectra were processed on a Silicon
Graphics Indy workstation using UXNMR (Bruker) software. Gener-
ally, data in both dimensions were multiplied by a sine-bell function
shifted by 90° prior to Fourier transformation and a polynomial base-
line correction applied to selected regions.
3 J. Gehrmann, personal communication.
TABLE I
Sequences of native and modified a-conotoxins
Single-letter amino acid codes are used. Heavy lines between cysteine
residues represent disulfide bonds.
nAChR Subtype Specificity of a-Conotoxin PnIA and Analogues36560










Rapid focal application of 500 mM ACh to dissociated rat
intracardiac ganglion neurons, in the presence of 100 nM atro-
pine, resulted in a characteristic biphasic inward current com-
prising an initial transient peak which rapidly decayed to a
steady-state current (Fig. 1, A and B). The ratio of peak to
steady-state current amplitude varied between neurons, which
may be attributable to the heterogeneous mRNA expression of
different nAChR subunits reported in rat intracardiac neurons
(19). The peak whole-cell ACh-evoked current in all neurons
was reversibly inhibited .95% by 1 mM mecamylamine (data
not shown), a non-selective nicotinic AChR antagonist (12).
Since inhibition of the steady-state current by the a-conotoxins
examined was variable, all measurements describe the inhibi-
tion of peak current. a-Conotoxin PnIA inhibited the ACh-
induced current in a concentration-dependent manner (Fig.
1A), with an IC50 of 14 nM. PnIA did not completely inhibited
the peak current, producing maximal reduction in amplitude of
87 6 2% (n 5 6) at a concentration of 10 mM (Fig. 1C). a-Cono-
toxin PnIB was less potent than PnIA, inhibiting the peak
ACh-induced current (Fig. 1B) with an IC50 value of 33 nM (Fig.
1C). PnIB also did not completely block the peak nicotinic
current, with a concentration of 10 mM, causing a maximum
reduction of only 68 6 3% (n 5 5) (Fig. 1C). PnIA and PnIB
were each effective at reducing ACh-induced current in all
neurons examined.
The potency of two substituted a-conotoxins [A10L]PnIA and
[N11S]PnIA to block the nicotinic ACh-induced current was
also examined. [N11S]PnIA was the least potent inhibitor of
the ACh-induced current in these neurons, having an IC50 of
375 nM, with 17 6 1% (n 5 4) of the current resistant to 10 mM
[N11S]PnIA (Fig. 2A). A plateau was not reached in the dose-
response relationship, but the fitted curve predicts a maximum
inhibition of 91% (Fig. 2C), similar to that achieved with PnIA.
Higher concentrations were not tested due to limited availabil-
ity of the toxin. [N11S]PnIA was effective in reducing the
ACh-induced current in all neurons examined. In contrast,
[A10L]PnIA was the most potent of the a-conotoxins examined.
However, the nicotinic ACh-induced current in ;20% of neu-
rons was insensitive to block by [A10L]PnIA. The IC50 value for
the [A10L]PnIA-sensitive component of the current was 1.4 nM,
with 56 6 6% (n 5 4) of the total nicotinic ACh-induced current
insensitive to block by [A10L]PnIA (Fig. 2C). The current re-
maining in the presence of a maximally effective concentration
of [A10L]PnIA was not inhibited further by a-bungarotoxin
(Fig. 2B), a selective inhibitor of neuronal nAChRs containing
the a7 subunit (20), but could be further reduced by either 200
nM EpI, which selectively inhibits receptors containing a3b2
and a3b4 subunits (3), or 200 nM PnIA (data not shown). In
cells insensitive to [A10L]PnIA, the peak current could be
inhibited by EpI (200 nM) (Fig. 3A) or PnIA.
a-Bungarotoxin inhibited the nicotinic ACh-induced current
in ;80% of neurons examined, and these results are included
FIG. 1. Effects of the native toxins, PnIA and PnIB, on the
nicotinic ACh-evoked currents in rat intracardiac neurons.
Rapid application of 500 mM ACh in the presence of atropine (100 nM)
evokes a characteristic biphasic response, with an initial peak which
rapidly decays to a steady-state level. Superimposed traces of whole-cell
ACh-induced currents in the absence (control) and presence of various
concentrations of PnIA (A) and PnIB (B). Inset, peak currents from A
shown on an expanded time scale. Horizontal bar, 50 ms. Inhibition of
the steady-state current by the conotoxins examined was variable,
hence, all measurements were of the peak current. Holding potential
was 280 mV in A, and 270 mV in B. C, dose-response relationship
obtained for the inhibition of the peak ACh-induced current by PnIA (l)
and PnIB (). IC50 values obtained from curve fitting were 14 and 33
nM, respectively.
FIG. 2. Effects of the modified a-conotoxins, [N11S]PnIA and
[A10L]PnIA, on the ACh-evoked current in rat intracardiac neu-
rons. A, cumulative addition of 200 nM and 2 mM [N11S]PnIA reduces
the ACh-evoked current in this neuron. Holding potential, 260 mV. B,
100 nM [A10L]PnIA blocks ;30% of the ACh-evoked current, and sub-
sequent addition of 100 nM a-bungarotoxin does not cause further
inhibition of the response. Holding potential, 290 mV. Vertical bar
represents 0.5 nA in A and 0.2 nA in B. C, dose-response relationship for
the inhibition of the peak nicotinic ACh-evoked current by [N11S]PnIA
() and [A10L]PnIA (E). IC50 values obtained from fits for [N11S]PnIA
and [A10L]PnIA were 375 and 1.4 nM, respectively.
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in Fig. 3C for comparison. The residual peak current remaining
following application of 1 mM a-bungarotoxin (58 6 5% of con-
trol, n 5 5), was not significantly different (p . 0.25) from the
current resistant to 1 mM [A10L]PnIA (56 6 6%, n 5 4), and
could be further inhibited by PnIB and PnIA (Fig. 3B). A
comparison of the residual current amplitudes obtained in the
presence of maximally effective concentrations of a-bungaro-
toxin, a-conotoxins, and mecamylamine are summarized in
Fig. 3C.
To determine if PnIA can inhibit the a3b4 nAChR subtype,
cytisine, which is more potent than ACh at activating the a3b4
receptor in a mammalian cell line (21), was used to activate
whole-cell currents. PnIA (1 mM) inhibited the current evoked
by cytisine (300 mM) by 37 6 5% (n 5 5) (data not shown), but
even at a concentration of 10 mM, PnIA blocked a smaller
proportion of the cytisine-evoked current than the ACh-evoked
current. The residual cytisine-induced current reflects an in-
creased contribution of a PnIA-insensitive nAChR subtype to
the whole-cell current in rat intracardiac neurons.
To accurately interpret the observed changes in activity of
the PnIA mutants, it was necessary to establish whether the
substitutions at positions 10 and 11 produced any changes to
the backbone structure of these peptides. Two-dimensional
TOCSY and NOESY 1H NMR spectra were recorded for the
peptides and were assigned using standard methods, as de-
scribed for the related a-conotoxin GI (22). Briefly, the TOCSY
spectra were used to correlate peaks to particular amino acid
types and the NOESY spectra were used to delineate the se-
quence specific location of these amino acids (23). Secondary
chemical shifts were then calculated by subtracting random
coil shifts (24) from the aH chemical shifts for each of the
constituent residues in the four peptides. These secondary
shifts are highly diagnostic of local structural elements (24).
Fig. 4 shows that the secondary shifts are almost identical for
all four peptides, suggesting that the structures are similar.
Further, the pattern of secondary shifts is consistent with the
overlapping three-dimensional structures of PnIA and PnIB
observed in the crystalline state derived by x-ray methods (6,
7). In particular, the pattern of negative secondary shifts in the
middle section of all four peptides is consistent with the re-
ported a-helix between residues 5 and 12 in PnIA and PnIB.
DISCUSSION
In contrast to a previous study, which found no activity of
intracerebral injections of PnIA or PnIB into rat brain (1), the
native a-conotoxins PnIA and PnIB both inhibit the nicotinic
ACh-induced whole-cell current in rat intracardiac ganglion
neurons in a dose-dependent manner. PnIA was 3-fold more
potent and able to inhibit ;90% of the ACh-induced current at
a maximally effective concentration, compared with ;70% for
PnIB. The modified toxin [N11S]PnIA was an order of magni-
tude less potent than PnIB but also caused maximal inhibition
of ;90%. [A10L]PnIA was an order of magnitude more potent
than PnIA (IC50 of 1.4 nM) but caused a maximal inhibition of
only ;45% of the peak current. The inhibition of ACh-evoked
currents by native (PnIA, PnIB) and modified a-conotoxins
([A10L]PnIA, [N11S]PnIA) are summarized in Table II. Hill
coefficients obtained from fits of the inhibitory dose-response
curves were consistently less than unity, the significance of
which is unclear, but are similar to those obtained for inhibi-
tion of a3b2 and a7 receptors expressed in oocytes by the
a-conotoxins, MII (4) and ImI (26), respectively.
Previous studies have demonstrated that ;80% of rat intra-
cardiac neurons express a7 subunits, based on the sensitivity of
the whole-cell ACh-induced current to a-bungarotoxin (25) and
mRNA expression of the a7 subunit (19). The IC50 value of 0.12
nM for a-bungarotoxin inhibition of the ACh-induced current
obtained in rat intracardiac neurons (25) is more than 4 orders
of magnitude lower than that obtained from a7 homomers
expressed in Xenopus oocytes (26) suggesting that the native a7
receptors are not a7 homomers. In this study, bath application
of a-bungarotoxin (1 mM) produced a maximal inhibition (42 6
5%) that was similar to that obtained previously in rat intra-
cardiac neurons (47 6 2%) (25), and similar to the maximal
FIG. 3. Effect of a-conotoxins and a-bungarotoxin on ACh-
evoked currents. A, [A10L]PnIA did not affect the ACh-evoked cur-
rent in this cell; however, subsequent application of 200 nM EpI inhib-
ited the current amplitude by ;50% (see Ref. 21). Holding potential,
270 mV. B, progressive inhibition of the ACh-evoked current by cumu-
lative addition of saturating concentrations of a-bungarotoxin, PnIB
and PnIA. Holding potential, 280 mV. Vertical bar represents 0.5 nA in
A and 0.3 nA in B. C, bar graph of the relative inhibition of the nicotinic
ACh-evoked current amplitude (mean 6 S.E.) at maximally effective
concentrations of PnIA, [A10L]PnIA, [N11S]PnIA, PnIB, a-bungaro-
toxin, and mecamylamine. *, p , 0.005; **, p , 0.0005.
FIG. 4. Secondary aH chemical shifts, i.e. differences between
observed chemical shifts and random coil shifts, for PnIA,
[A10L]PnIA, [N11S]PnIA, and PnIB. The different mutants are
identified by their amino acids at positions 10 and 11; the sequences at
all other positions are identical. The random coil shifts used include
corrections for residues preceding Pro in the sequence (24).
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inhibition seen in the present study with [A10L]PnIA. Further-
more, inhibition of the whole-cell current by a-bungarotoxin
and [A10L]PnIA was not additive, suggesting that [A10L]PnIA
and a-bungarotoxin selectively inhibit the same a7 component
in these neurons. The potency and selectivity of conotoxin
[A10L]PnIA make it the best conotoxin-derived pharmacologi-
cal probe for a7 receptors. Previous studies on a-conotoxin ImI
have suggested that the major binding determinants for the a7
receptor are found in the first loop (Asp5-Pro6-Arg7) with an
additional contribution to binding made by Trp10 in the second
loop (22, 28). Inspection of the primary (see Table I) and terti-
ary structures of [A10L]PnIA and ImI suggest that conotoxin
[A10L]PnIA most likely binds at a different “microsite.” More
detailed structure-function studies will be required to deter-
mine the precise nature and site of interaction of [A10L]PnIA
with the a7 receptor.
The a-conotoxin EpI isolated from Conus episcopatus has
been shown previously to block a3b2 and a3b4 nicotinic recep-
tors in rat intracardiac ganglion neurons (3). Both EpI and
PnIA are able to further reduce the nicotinic ACh-induced
current in the presence of a maximal concentration of
[A10L]PnIA or a-bungarotoxin. [A10L]PnIA does not cause
further block of either the ACh- or cytisine-evoked current in
the presence of 1 mM PnIA (n 5 3, data not shown), indicating
that PnIA blocks the a7 component as well as additional com-
ponents of the nAChR-mediated current in these neurons. The
ACh-induced current in all cells was inhibited ;90% by
[N11S]PnIA, suggesting that substitution of asparagine at po-
sition 11 for serine does not affect PnIA subtype selectivity,
despite a ;30-fold reduction in potency. The results with
[A10L]PnIA suggest that position 10 has an important influ-
ence on selectivity, with the larger, more hydrophobic leucine
conferring selectivity for the a7 subunit of the nAChR and
increased potency.
The NMR data clearly confirm that the changes in potency
and selectivity brought about by mutations at positions 10 and
11 are not due to structural changes. aH secondary NMR
chemical shifts provide a very sensitive fingerprint of both local
and global structural change and confirm that the backbone
structures are identical. The signs and magnitudes of the sec-
ondary shifts show that, like PnIA and PnIB, both mutants
possess an a-helix between residues 5 and 12. The highly
conserved nature of this helix upon substitution contrasts with
the variation in the nature and extent of the helix when the
number of amino acids between conserved cysteine residues is
changed, as seen from our recent structural studies on cono-
toxins MII (29), GI (22), and ImI (30). Inspection of the crystal
structures of PnIA and PnIB shows that residues 10 and 11 are
both on the face of the helix exposed to the solvent, rather than
packed toward the disulfide core of the peptides (see Fig. 5).
The high surface exposure favors direct interactions of these
residues with complementary binding sites on nAChRs. The
larger hydrophobic surface at residue 10 in [A10L]PnIA is
presumably complementary with binding to the a7, but unfa-
vorable for binding to the other subunit combinations in these
neurons.
Although nAChRs are widely expressed throughout the ver-
tebrate nervous system (31), their precise function in many
cases is poorly understood. Neuronal nAChRs containing the
a7 subunit have been identified in chick sympathetic neurons
(32), rat hippocampal neurons (33), and chick ciliary ganglion
(34). However, the physiological role of the a7 component in
many of these systems remains unclear. Presynaptic nAChRs
containing the a7 subunit have been shown to modulate neu-
rotransmitter release (35, 36), and there is evidence that the
receptors containing the a7 subunit are involved in synaptic
transmission in chick ciliary ganglia (37). The a7 subunit does
not appear to form functional postsynaptic nAChRs in rat
parasympathetic neurons, as synaptic transmission in the rat
submandibular ganglion is not affected by either a-bungaro-
toxin (1 mM) or [A10L]PnIA. Bath application of PnIA (1 mM),
however, causes partial inhibition of synaptic transmission in
rat parasympathetic ganglia, reducing excitatory postsynaptic
potential amplitude by approximately 35%.4
The range of selectivities of native and modified a-conotoxins
PnIA and PnIB for mammalian nAChRs makes these peptides
valuable new tools for investigating the subunit composition of
neuronal nAChRs at a functional level. At a molecular level,
their small size lends them to relatively easy synthesis and
modification and makes them ideal tools for investigating the
structure function relationship of the subunits, which consti-
tute neuronal nAChRs. This study shows the importance of
individual a-conotoxin residues for defining both affinity and
selectivity. With the four peptides investigated, it was possible
to dissect four pharmacologically distinct nAChR-mediated
currents, including a component mediated by nAChRs contain-
ing a7 subunits in rat intracardiac ganglion neurons. The
nAChR subunit combinations giving rise to the other three
4 A. B. Smith and D. J. Adams, unpublished observations.
TABLE II
Inhibition of ACh-evoked current amplitude by a-conotoxins
Hill coefficients and percentage of maximal inhibition (6 95% confi-
dence limits) were calculated from the fitted curve (“Experimental








PnIA 14 0.80 87 6 2 41
[A10L]PnIA 1.4 0.71 46 6 2 33
[N11S]PnIA 375 0.78 91 6 3 24
PnIB 33 0.67 71 6 3 32
FIG. 5. Ribbon representation of the a-conotoxin PnIA struc-
ture (6) showing the location of amino acid residues 10 (Ala;
green) and 11 (Asn; blue) on the exposed face of the helix back-
bone (red). The disulfide bonds connecting Cys2–Cys8 and Cys3–Cys16
are shown in yellow.
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components of the ACh-evoked current in these neurons re-
main to be fully elucidated, but are likely to include different
combinations of those a and b subunits identified previously in
single cell reverse transcription-polymerase chain reaction
studies (19).
Acknowledgments—We thank John Gehrmann for helpful comments
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